Drie bedrijven opgericht of mede-opgericht door Truffle vertegenwoordigen 30% van de totale waardering van de hoogste BioMedTech-marktkapitalisaties van Euronext Parijs. Ze behoren ook tot de toppresteerders van 2020.

PARIJS– (BUSINESS WIRE) – Truffle Capital:

1. Drie toonaangevende BioMedTech-bedrijven, opgericht of mede-opgericht en ondersteund door Truffle Capital sinds hun oprichting, genereren uitstekende prestaties in 2020

Vanaf vandaag hebben Abivax (EPA: ABVX), Carbios (EPA: ALCRB) en Carmat (EPA: ALCAR) een gezamenlijke kapitalisatie van 1,3 miljard euro (respectievelijk 497, 443 en 379 miljoen euro) en behoren zij tot de best presterende aandelen van 2020 genoteerd op Euronext Parijs (waaronder Carbios op de 1e plaats; onder de bedrijven met een kapitalisatie tussen 200 miljoen en 2 miljard euro; zie tabel hieronder).Deze drie bedrijven ontwikkelen allemaal radicale innovaties die gericht zijn op een revolutie in de medische sector of de bescherming van het milieu.

Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies

Three companies founded or co-founded by Truffle represent 30% of the total valuation of the highest BioMedTech market caps of Euronext Paris. They are also among the 2020 top stock performers.

PARIS–(BUSINESS WIRE)– Truffle Capital:

1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020

As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1^st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.

Here are the latest companies’ breaking news for these three companies:

• November 19, 2020: Carbios, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios published a major scientific article in Nature, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage.

  Link: News/Carbios/First Plastic Bottle from Recycled Textile
  Link: News/Carbios/Nature Cover Page

• December 22, 2020: Abivax, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax ABX464 drug candidate was declared a National Covid-19 Research Priority by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year.

  Link: News/Abivax/National Covid-19 Research Priority

• December 23, 2020: Carmat, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world’s most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).

  Link: News/Carmat/CE Marking

For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios: www.carbios.fr; Abivax: www.abivax.com and Carmat: www.carmatsa.com).

These companies and their achievements are Truffle Capital’s signature as an entrepreneur-investor company: sourcing radical innovations in biotechnology and medical devices from around the world to build leading companies in France and support them towards advanced development stages.

Philippe Pouletty, M.D. co-founder and CEO of Truffle Capital, mentions: “We are proud of these three French companies that would not have existed without Truffle. Contributing to saving lives or protecting our planet, thanks to exceptional scientific research and technologies and to international management teams, fosters the emergence of future World leaders in France, while generating a very good return on investment for Truffle Capital’s funds. We intend to amplify our efforts with our new BioMedTech and Medeor funds, to benefit patients around the world and our investors.”

Sources: Price per share variation (%) from 12/31/2019 to 12/31/2020; market capitalization on 01/22/2021. Companies in the diagnostics sector or with market capitalizations less than 200 million euros or over 2 billion euros as of January 1, 2020 were excluded. This ranking was established based on Euronext data.

2. New BioMedTech Companies created by Truffle Capital in Major Healthcare Sectors

Truffle continues to create and support future BioMedTech leaders aiming to treat life threatening diseases. Truffle Early-Stage BioMedTech Funds, which closed at the end of 2019, have already enabled the financing of 8 BioMedTech companies built on promising radical innovations.

• Affluent Medical (Aix en Provence) is developing four minimally invasive medical devices to treat cardiac, vascular and urologic diseases, which are already at an advanced clinical development stage;
• Artedrone (Paris) is aiming to design revolutionary autonomous microrobots allowing interventional radiologists to treat or prevent cerebrovascular accidents without using catheters;
• Bariatek (Paris) is developing a minimally invasive medical device to treat obesity;
• Caranx Medical (Nice) is developing autonomous surgical robots, for vascular and abdominal surgery;
• Diaccurate (Paris) is developing novel anti-cancer and anti-viral drugs based on breakthrough immuno-oncology mechanisms;
• HoliStick Medical (Paris) is developing a medical device to close pathological holes between the right and left heart (PFO) in order to prevent strokes;
• PKMed (Lyon), is developing biocompatible 3D implants to enable local drug delivery or to promote the genesis of functional tissues and organs following cell therapy;
• Skinosive (Marseille) is developing bioadhesive technologies to increase the effectiveness and safety of UV filters and other dermato-cosmetic compounds.

3. MEDEOR, Truffle New Late-Stage BioMedTech Fund, expects a first closing before summer

Truffle new MEDEOR Fund aims to complement Truffle’s BioMedTech financing tools for BioMedTech companies, from inception to commercial stages. It has a clear industrial objective: invest at least €600 million in future BioMedTech world leaders developing advanced-stage medical devices (pre-commercial or commercial stage, for 70%) or innovative drugs (phase II & III clinical studies, for 30%). MEDEOR will always be lead investor and major proactive shareholder and board member, to build in France technological leaders that will revolutionize surgery and medicine. French institutional investors and French government granted MEDEOR the “Tibi” label, a French government initiative to encourage LP’s to invest in the best funds.

Thanks to MEDEOR, Truffle Capital intends to continue to lead French BioTech and MedTech companies towards commercial and international medical success.

4. Truffle : a High Performance business model launched twenty years ago

Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital’s mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.

2020 was marked by the launch of new innovative projects in its two areas of expertise (BioMedTech and FinTech/InsurTech) and by very significant advances in the field of Biotechnology and Medical Devices.

******

For more information: www.truffle.com — Twitter: @trufflecapital

View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005496/en/

Contacts

Truffle Capital Investor Relations: Maud Lazare – maud@truffle.com

Media Relations Agency – DGM Conseil
Quentin Hua – quentin.hua@dgm-conseil.fr (+ 33 6 28 63 27 29)

Thomas de Climens – thomasdeclimens@dgm-conseil.fr (+33 6 14 50 15 84)

Hugues Schmitt – h.schmitt@dgm-conseil.fr
Olivier Labesse – labesse@dgm-conseil.fr